Metagenomi (MGX) Competitors $1.88 +0.05 (+2.73%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$1.88 0.00 (-0.21%) As of 09/17/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MGX vs. MRNA, NGNE, LFCR, MREO, ACB, RNAC, CADL, MNPR, NMRA, and LXEOShould you be buying Metagenomi stock or one of its competitors? The main competitors of Metagenomi include Moderna (MRNA), Neurogene (NGNE), Lifecore Biomedical (LFCR), Mereo BioPharma Group (MREO), Aurora Cannabis (ACB), Cartesian Therapeutics (RNAC), Candel Therapeutics (CADL), Monopar Therapeutics (MNPR), Neumora Therapeutics (NMRA), and Lexeo Therapeutics (LXEO). These companies are all part of the "pharmaceutical products" industry. Metagenomi vs. Its Competitors Moderna Neurogene Lifecore Biomedical Mereo BioPharma Group Aurora Cannabis Cartesian Therapeutics Candel Therapeutics Monopar Therapeutics Neumora Therapeutics Lexeo Therapeutics Metagenomi (NASDAQ:MGX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability. Which has preferable earnings and valuation, MGX or MRNA? Metagenomi has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetagenomi$52.29M1.35-$78.06M-$2.36-0.80Moderna$3.24B3.01-$3.56B-$7.53-3.32 Is MGX or MRNA more profitable? Moderna has a net margin of -94.31% compared to Metagenomi's net margin of -257.99%. Moderna's return on equity of -25.96% beat Metagenomi's return on equity.Company Net Margins Return on Equity Return on Assets Metagenomi-257.99% -37.84% -27.15% Moderna -94.31%-25.96%-20.09% Do insiders & institutionals have more ownership in MGX or MRNA? 75.3% of Moderna shares are owned by institutional investors. 17.8% of Metagenomi shares are owned by insiders. Comparatively, 11.0% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media refer more to MGX or MRNA? In the previous week, Moderna had 24 more articles in the media than Metagenomi. MarketBeat recorded 24 mentions for Moderna and 0 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.95 beat Moderna's score of 0.51 indicating that Metagenomi is being referred to more favorably in the media. Company Overall Sentiment Metagenomi Positive Moderna Positive Which has more risk & volatility, MGX or MRNA? Metagenomi has a beta of -0.17, indicating that its stock price is 117% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500. Do analysts recommend MGX or MRNA? Metagenomi currently has a consensus target price of $10.00, suggesting a potential upside of 431.91%. Moderna has a consensus target price of $41.81, suggesting a potential upside of 67.25%. Given Metagenomi's stronger consensus rating and higher possible upside, equities research analysts plainly believe Metagenomi is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metagenomi 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Moderna 4 Sell rating(s) 14 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.05 SummaryModerna beats Metagenomi on 9 of the 16 factors compared between the two stocks. Get Metagenomi News Delivered to You Automatically Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGX vs. The Competition Export to ExcelMetricMetagenomiMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.69M$2.53B$5.74B$10.30BDividend YieldN/A59.99%5.86%4.62%P/E Ratio-0.8023.2976.8526.52Price / Sales1.35486.45453.0387.93Price / CashN/A169.8537.2260.63Price / Book0.305.2913.686.31Net Income-$78.06M$32.95M$3.29B$271.37M7 Day Performance-0.53%-1.29%-0.75%0.57%1 Month Performance-2.08%3.50%3.84%6.20%1 Year Performance-29.32%-3.48%82.85%28.33% Metagenomi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGXMetagenomi2.8184 of 5 stars$1.88+2.7%$10.00+431.9%-31.6%$68.69M$52.29M-0.80236High Trading VolumeMRNAModerna4.5231 of 5 stars$24.83-1.2%$42.88+72.7%-65.3%$9.78B$3.24B-3.305,800NGNENeurogene1.9329 of 5 stars$19.45-2.5%$46.17+137.4%-56.0%$284.73M$930K-4.5190Positive NewsLFCRLifecore Biomedical0.8632 of 5 stars$7.29-3.2%$8.00+9.7%+51.7%$281.68M$128.87M-5.56690MREOMereo BioPharma Group2.4011 of 5 stars$1.79+1.1%$7.40+313.4%-56.2%$281.43M$10M-25.5740Positive NewsACBAurora Cannabis0.552 of 5 stars$4.84-1.4%N/A-16.3%$277.19M$246.72M-25.471,130Positive NewsRNACCartesian Therapeutics2.3745 of 5 stars$10.19-4.2%$40.00+292.5%-45.0%$276.66M$38.91M-0.1964Positive NewsCADLCandel Therapeutics2.4926 of 5 stars$5.10+2.0%$20.00+292.2%-31.1%$274.48M$120K-7.3960Positive NewsMNPRMonopar Therapeutics2.158 of 5 stars$41.48-6.2%$69.57+67.7%+1,501.9%$272.77MN/A-12.4610Analyst ForecastGap UpNMRANeumora Therapeutics2.6828 of 5 stars$1.66-1.2%$7.14+330.3%-87.6%$272.07MN/A-1.06108News CoveragePositive NewsAnalyst DowngradeGap DownLXEOLexeo Therapeutics2.641 of 5 stars$5.25+4.6%$15.33+192.1%-43.9%$271.09M$650K-1.6158Positive News Related Companies and Tools Related Companies Moderna Competitors Neurogene Competitors Lifecore Biomedical Competitors Mereo BioPharma Group Competitors Aurora Cannabis Competitors Cartesian Therapeutics Competitors Candel Therapeutics Competitors Monopar Therapeutics Competitors Neumora Therapeutics Competitors Lexeo Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGX) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTen Bucks, Five Minutes... Could Send You Up to $8K QUARTERLYDOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredWhy Peter Thiel Hid Gold in a VaultSilicon Valley billionaires hiding gold in vaults? Peter Thiel’s Palantir quietly diverted tens of millions...Golden Portfolio | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metagenomi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MGX Stock Alerts